Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aethlon Medical, Inc. (OQ:AEMD)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 11555 Sorrento Valley Road, Suite 203
SAN DIEGO CA 92121
Tel: N/A
Website: https://www.aethlonmedical.com
IR: See website
Key People
James B. Frakes
Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President - Finance, Company Secretary, Director
Guy F. Cipriani
Chief Operating Officer, Senior Vice President
Lee D. Arnold
Chief Scientific Officer
Steven P. Larosa
Chief Medical Officer
   
Business Overview
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
Financial Overview
For the nine months ended 31 December 2023, Aethlon Medical, Inc. revenues was not reported. Net loss increased 2% to $9.8M. Higher net loss reflects Payroll and related expenses increase of 33% to $4.2M (expense), Professional Fees increase of 8% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.39 to -$3.95.